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Call for patients with familial pancreatic disease -
the EUROPAC register
We are establishing a national UK register (EUROPAC) offamilies
with hereditary pancreatitis, familial pancreatic cancer and when
pancreatic cancer has occurred as part of a familial cancer
syndrome. This collaboration in Liverpool is between the
Department of Clinical Genetics (Dr Ian Ellis) and the Academic
Department of Surgery (Professor John Neoptolemos). The data
and samples are collected on behalf of ESPAC (The European
Study Group for Pancreatic Cancer), Professor Markus Buichler,
Berne, and Professor Hans Beger, Ulm. The study will collaborate
with Dr David Whitcomb of the Midwest Multicenter Pancreatitis
study group in the USA. We aim to recruit families who are
prepared to donate blood samples for DNA studies. We hope to
gain a clearer understanding of the genetic relationship between
hereditary pancreatitis and familial pancreatic cancer, and to
develop screening protocols for at-risk individuals.
The risk of developing pancreatic cancer is greatly increased in
families with hereditary pancreatitis, or certain familial cancer
syndromes. Familial pancreatic cancer may also occur indepen-
dently of either of these, with an apparently dominant mode of
inheritance, but the genetics of this are at present poorly under-
stood. There is some evidence that DNA analysis of cells from
4-7March 1998
3rd International Symposium on Drug Resistance in
Leukemia and Lymphoma
Amsterdam, The Netherlands
Further informationfrom:
VU Conference Service, De Boelelaan 1105, 1081 HV
Amsterdam, The Netherlands, Tel: +31 20 444 5790,
Fax: +31 20 444 5825
23-25 March 1998
Joint Meeting of the Association for Radiation
Research and the DNA Repair Network - Radiation
Research: Signals for the future
Lancaster, UK
Further informationfrom:
Professor T J McMillan, Division ofBiological Sciences, Lancaster
University, Lancaster LA1 4YQ, UK. Tel: + 44 (0)1524 594486
Fax: + 44 (0)1524 843 854. Email: t.mcmillan@lancaster.ac.uk
10-14 May 1998
The 13th International Congress of Cytology
Tokyo, Japan
pancreatic fluid may be valuable in detecting premalignant changes
that can predict the development ofpancreatic adenocarcinoma.
The criteria for inclusion in the study are as follows:
Hereditarypancreatitis
Three relatives with chronic pancreatitis in the absence of ethanol
dependence, hypercalcaemia or obstructive cause.
Familialpancreatic cancer
Two first-degree relatives with pancreatic ductal adenocarcinoma;
three or more relatives with pancreatic ductal adenocarcinoma;
pancreatic ductal adenocarcinoma in any two relatives for whom
the sum oftheir ages is less than 110 years.
Otherfamilial cancersyndromes
A single documented pancreatic ductal adenocarcinoma in any
family with an established familial cancer syndrome, for example
BRCA2, FAMMM, A-T, HNPCC or FAP.
We would be interested in incorporating suitable families into the
study. Please contact Fiona McRonald at Clinical Genetics, Alder
Hey Children's Hospital, Eaton Road, Liverpool L12 2AP, UK, or
on 01512525905.
Thank you for your help.
Further informationfrom:
Interuational Medical Communications Center, Tokyo Medical
College, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo 160, Japan.
Tel: +81 3 3342 6111 (ext. 5845), Fax: +81 3 3342 0860, Email:
iactokyo@gol.com http://www2.gol.com /users/iactokyo
28-30 May 1998
3rd Educational Convention of the European School of
Oncology
Turin, Italy
Further informationfrom:
ACTA Organising Secretariat, via Caboto 44, 10129 Turin, Italy.
Tel: +39 11 591871 or 599498 Fax: +39 11 590833
1-3 June 1998
Radiology 1998- Imaging, Science and Oncology
Birmingham, UK
Further informationfrom:
Ms June Clark, Conference Manager, Radiology Secretariat
Office, 36 Portland Place, London WIN 4AT, UK.
Tel: +44 (0) 171 436 7807 Fax: +44 (0) 171 255 3209
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1-4 Jl,ne 1998
Critical Issues in Tumor Microcirculation, Angiogenesis
and Metastasis: Biological Significance and Clinical
Relevance. 13th Annual Offering - A Continuing
Education Course
Harvard Medical School and Massachusetts General
Hospital, Boston, MA, USA
kuulier i/l(lifO)l/)1(lti()ll fmii:1.
Ms C Lxons. Adiminlistrtator. Radiation Oncology. Maxssachusetts
Genierll Hospital. Boston. MA 021 14. USA.
Tel:+ 161772644083 Fax:+ 1 617 726 4172
14-17 Jlmwe 1998
ESPOIO European Conference of Psychosocial
Oncology
Stockholm, Sweden
krt lOwrl' inl1 forutili0/ from7:
ESPOIO Stockholimi Convention Bureau. Box 691 1. S-102 39
Stockhiolim. Sweden.
Fatx: + 46 8 34 84 41 Email: ESPOIOC@Stocon.se
19-20 Jlmwe 1998
5th International Conference on Long-term
Complications of Treatment of Children and
Adolescents for Cancer
Queen's Landing at Niagara-on-the-Lake, Ontario, Canada
F'llrether inlfiiOrOitI onfil-oln:
Dan1iel M GreeIn. MD. Department of Pediatr-ics. Ros\ell
Palrk Caniicer IIStitute. Elm and Caritoi Streets. Bufftlo.
NY 14263.Tel: (716)845 2334:Fax: (716)845 8003:
Email: -eren Casc3 101 .mted.buIffalo.edIu
20-24 Jlunte 1998
Second Cuneo Lung Cancer Conference
Terme di Valdieri, Italy
kuurtlhwr inifrll(ationl twin)1.:
CLuIneo LuLng Caiicer- StUdy GrouIp (CuLLCaSG).
Viai RomitaL. 15 1 2011 Borgo S Dalmnazzo. Cunleo. Italy.
Tel: 39171 260065
22-24 JiilvI1998
lXth Symposium Mammographicum
University of York, Heslington, York, UK
Frt'iw,'t/(R inftormaltion fi'OOI:
Svmlposi urn Mammlilographicuml98 Secretalrialt.Congrless House.
65S West Drive.Chea. ilSutton.Surrey' 5M2 7NB. UK.
Tel: +44(0) 181 661 0877:
Falx: +44(0) 181 661 90)36
El-i-citlciti
Kinetics of mouse jejunum radiosensitization by 2',2'-
difluorodeoxycytidine (gemcitabine) and its relation-
ship with pharmacodynamics of DNA synthesis
inhibition and cell cycle redistribution in crypt cells
V Gr6goire, M Beauduin, J-F Rosier, B De Coster, M
Bruiaux, M Octave-Prignot and P Scalliet
Br] JCtmcer-76: 1315-1321
Due to an error in film output figures I and 3 of this paper were
incorrect wvhen the paper wvas published. The publishers wish to
apologise to the aLuthors. editors and readers for this serious error.
The correct figLires aire reproduced below.
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Figure 1 Effect of dFdC (150 mg kg-') on the tolerance of mouse jejunum
to single-dose irradiation. Mice were treated by irradiation alone (0), dFdC
given 3 h before irradiation (-) or dFdC given 48 h before irradiation (A).
Three days and 14 h after irradiation. mice were killed, the jejunum was
removed, fixed in Bouin, paraffin embedded and stained with trichrome. The
number of regenerated crypts per circumference was counted in two differenl
sections per mouse. Each point is the average of 6 or 7 mice.
Dose-response curves were fitted by a least square regression analysis
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Figure 3 Pharmacodynamics of DNA synthesis inhibition (-) and kinetics
of mitotic index (0) in jejunal crypt cells. Mice were given 150 mg kg-' dFdC
and, at 0, 3.5, 6, 12.5, 18, 24, 36 and 48 h after drug administration, jejunum
was harvested and fixed in 10% neutral-buffered formalin. S-phase cells
were labelled with BrdUrd (60 mg kg-') 30 min before tissue harvest.
Sections were processed for immunohistochemical detection of BrdUrd-
labelled nuclei using a specific antibody for BrdUrd-containing DNA.
Labelling and mitotic indices were determined in two transversal jejunal
sections per animal. Each point is an average (+ s.e.m.) of three mice
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